| REGENXBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US75901B1070 / A140E0 |
| RB0 (Frankfurt) / RGNX (NASDAQ) |
| FRA:RB0, ETR:RB0, RB0:GR, NASDAQ:RGNX |
| - |
| https://www.regenxbio.com.. |
|
Regenxbio Inc. is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies to treat genetic disorders through its proprietary NAV Technology Platform. This platform utilizes recombinant adeno-associated ..
>Volltext.. |
| 535.84 Mio. EUR |
| 620.64 Mio. EUR |
| 76.95 Mio. EUR |
| -211.3 Mio. EUR |
| -254.09 Mio. EUR |
| -4.9 EUR |
| 217.63 Mio. EUR |
| 13.34 Mio. EUR |
| -204.82 Mio. EUR |
| 2.12 |
| -47.53% |
| -72.21% |
| - |
| - |
| - |
| REGENXBIO |
| 02.07.26 |